Publications at Sabanci University

  • Parlar A, Sayitoglu EC, Ozkazanc D, Georgoudaki AM, Pamukcu C, Aras M, Josey BJ, Chrobok M, Branecki S, Zahedimaram P, Ikromzoda L, Alici E, Erman B, Duru AD, Sutlu T. Engineering antigen-specific natural killer cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer. Eur J Immunol. 2019 May 4.
  • Chrobok M, Dahlberg CIM, Sayitoglu EC, Beljanski V, Nahi H, Gilljam M, Stellan B, Sutlu T, Duru AD, Alici E. Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. Cancers (Basel). 2019 Jan 10;11(1). pii: E69. doi: 10.3390/cancers11010069.
  • Kahraman T, Gucluler G, Simsek I, Yagci FC, Yildirim M, Ozen C, Dinc A, Gursel M, Ikromzoda L, Sutlu T, Gay S and Gursel I. Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet’s Disease severity. J Extracell Vesicles. 2017 Feb 28;6(1):1284449.
  • Duru AD, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B, Gahrton G, Nahi H, Alici E. Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLoS One. 2015 Sep 17;10(9):e0138248.
  • Bestas B, Moreno PM, Blomberg KE, Mohammad DK, Saleh AF, Sutlu T, Nordin JZ, Guterstam P, Gustafsson MO, Kharazi S, Piatosa B, Nordin JZ, Roberts TC, Behlke MA, Wood MJ, Gait MJ, Lundin KE, El Andaloussi S, Mansson R, Berglöf A, Wengel J and Smith CI. Splice-correcting oligonucleotides restore BTK function in X-linked agammagloblunemia model. J. Clin. Invest. 2014 Sep 2;124(9):4067-81.

Publications before Sabanci University

  • Sutlu T, Alici E, Gahrton G, Nahi H.  In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidéne et al. Med Oncol. 2013 Jun;30(2):569.
  • Sutlu T, Gilljam M, Stellan B and Alici E. Inhibition of intracellular anti-viral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Human Gene Therapy. 2012 Oct;23(10):1090-100.
  • Elsheikh E, Genead R, Danielsson C, Wärdell E, Andersson A, Kjaeldgaard A, Sundström E, Sutlu T, Grinnemo KH, Sylvén C. Isolation and Characterization of the SSEA-1+ Progenitor Cells from the Human Embryonic Heart. J Cytol Histol. 2011 Sep 2:122.
  • Sutlu T, Alici E. Ex vivo expansion of natural killer cells: a question of function. Cytotherapy2011 Jul;13(6):767-8.
  • Nahi H, Sutlu T, Alici E, Gahrton G. Clinical Impact of chromosomal aberrations in multiple myeloma. J Intern Med. 2011 Feb;269(2):137-47.
  • Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, Alici E. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy. 2010 Dec;12(8):1044-55.
  • Gahrton C, Nahi H, Jansson M, Wallblom A, Alici E, Sutlu T, Samuelsson J, Gahrton G. Constitutional inv(3) in myelodysplastic syndromes. Leuk Res. 2010 Dec;34(12):1627-9.
  • Georgoudaki AM, Sutlu T, Alici E. Suicide gene therapy for graft-versus-host disease. Immunotherapy. 2010 Jul;2(4):521-37.
  • Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Björkström NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringdén O, Ljunggren HG, Dilber MS. Safety analysis of an ex-vivo expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009 Sep;1(5):753-64.
  • Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009 Aug;266(2):154-81.
  • Paul E, Sutlu T, Deneberg S, Alici E, Björkstrand B, Jansson M, Lerner R, Wallblom, A, Gahrton G, Nahi H. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncol Rep. 2009 Jul;22(1):137-42.
  • Sutlu T., Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H. The prognostic significance of 8p21 deletion in multiple myeloma. Brit J Haematol. 2009 Jan;144(2):266-8.
  • Alici E, Sutlu T, Dilber MS. Retroviral gene transfer into primary human natural killer cells. Methods Mol Biol. 2009;506:127-37
  • Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, and Dilber MS. Autologous anti-tumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008 Mar 15;111(6):3155-62.
  • Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, Dilber MS. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol. 2007 Dec;35(12):1839-46.
  • Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 2007 Sep;21(11):2664-71.
  • Bilecen K, Ozturk UH, Duru AD, Sutlu T, Petoukhov MV, Svergun DI, Koch MH, Sezerman UO, Cakmak I, Sayers Z. Triticum durum metallothionein. Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling. J Biol Chem. 2005 Apr 8;280 (14):13701-11.